{"id":27221,"date":"2021-07-02T06:00:00","date_gmt":"2021-07-02T06:00:00","guid":{"rendered":"http:\/\/539b9efbe2b893dcb33377db1048eef7"},"modified":"2024-11-03T15:14:36","modified_gmt":"2024-11-03T15:14:36","slug":"poorer-survival-in-obese-colorectal-cancer-patients-possibly-linked-to-lower-chemotherapy-doses-esmo-world-gi-2021-press-release","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/poorer-survival-in-obese-colorectal-cancer-patients-possibly-linked-to-lower-chemotherapy-doses-esmo-world-gi-2021-press-release\/","title":{"rendered":"Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower Chemotherapy Doses [ESMO World GI 2021 Press Release]"},"content":{"rendered":"

LUGANO, Switzerland – Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO World Congress on Gastrointestinal Cancer 2021<\/a> (1). Further findings showed that cumulative relative chemotherapy dose was associated with survival so may explain the poorer survival that has been seen in obese patients receiving adjuvant chemotherapy for colorectal cancer. (2)<\/p>\n

\u201cAdjuvant chemotherapy is dosed according to a person\u2019s body surface area, which is calculated from their height and weight. But in obese patients (with a high body mass index (BMI), and who are more likely to have high BSAs), doses are often capped, or based on an idealised weight, because of concern that large doses might increase side-effects. This means that obese patients may receive proportionately lower doses of chemotherapy\u201d reported lead author Corinna Slawinski, from the Division of Cancer Sciences, University of Manchester, UK.<\/p>\n

\u201cOur study has demonstrated an association between increasing body mass index and modest reductions in the cumulative relative dose of adjuvant chemotherapy in patients with colorectal cancer. And we also saw an association between increased cumulative relative dose and improved survival,\u201d she said. \u201cThis supports the recently published ASCO guidance that full, weight-based chemotherapy doses should be used to treat obese adult patients\u201d (3)<\/p>\n

Commenting on the findings, Elizabeth Smyth, Addenbrooke\u2019s Hospital in Cambridge, UK, member of the ESMO Faculty for Gastrointestinal tumours, said: \u201cDose reductions for high BMI may be associated with lower cure rates in resected colon cancer treated with adjuvant chemotherapy.\u201d She added: \u201cAdjuvant chemotherapy has the potential to cure patients with residual micrometastatic disease following curative surgery, so it is important that we maximise the benefits for all patients.\u201d<\/p>\n

A number of previous studies have shown that obese patients with colorectal cancer have worse outcomes than non-obese patients. But limitations with these studies made it difficult to draw conclusions as to whether having a higher body mass index was directly associated with survival or if the association was due to other factors such as treatment (i.e. dose administered).<\/p>\n

\u201cOne important factor is how chemotherapy doses are calculated for individual patients. We carried out our study to better understand the relationship between BMI, chemotherapy dosing and survival in colorectal cancer,\u201d explained Slawinski.<\/p>\n

The OCTOPUS study analysed data for 7269 patients receiving adjuvant chemotherapy after curative surgery for colon and\/or rectal cancer in four large, randomised trials. The researchers examined the relationship between BMI and chemotherapy dosing and the relationship between chemotherapy dosing and survival.<\/p>\n

\u201cWe looked at two ways of measuring how much chemotherapy had been received as a proportion of actual-to-expected standard doses: average cumulative relative dose (ACRD) and average relative dose intensity (ARDI).\u201d ACRD is the proportion of the total expected standard dose (per unit of body surface area) over the whole chemotherapy course that has actually been received. ARDI however, also takes into account the duration of treatment, and is the proportion of the expected standard dose intensity (the total dose per unit of BSA, divided by the number of weeks of treatment) that has actually been received. With both measures averaged over the number of drugs in the regimen, and expressed as a percentage.<\/p>\n

Results showed that 5% increments in ACRD were significantly associated with improvements in disease-free survival (hazard ratio 0.953, 95% confidence interval 0926, 0.980, p=0.001). Overall survival was also associated with ACRD. However, there was no significant association with ARDI. Slawinski suggested that the lack of association between survival and ARDI may be because ARDI is a less sensitive measure of reductions in total (cumulative) dose of chemotherapy.<\/p>\n

Further findings showed that each BMI increase of 5kg\/m2<\/sup> was associated with a 2% reduction in the relative dose of chemotherapy in the first cycle of chemotherapy and 1% reductions in both ACRD and ARDI. This means an obese patient with a BMI of 37.5kg\/m2<\/sup> would have a 3% reduction of ACRD and ARDI compared to a non-obese patient with a BMI of 22.5kg\/m2<\/sup>.<\/p>\n

\u201cThese results showed that elevated BMI is associated with a reduced relative dose of chemotherapy in the first treatment cycle and a modest reduction in ACRD. These indirect effects through sub-optimal treatment might explain poorer survival in obese patients, rather than direct effects of obesity resulting from, for example, tumour biology,\u201d concluded Slawinski. \u201cOur results so far support giving obese patients a full dose of chemotherapy based on their body weight. But we are still exploring toxicity data, examining the relationship between BMI, dose capping, toxicity and survival,\u201d she cautioned. \u201cToxicity has the potential to reduce quality of life and can be life threatening. And there may also be other reasons for reducing chemotherapy doses, such as comorbidities, so it is important that dosing and treatment decisions are individualised to the patient.\u201d<\/p>\n

Smyth agreed: \u201cThe main message from this study is that we should consider whether dose reductions are necessary in patients with a high BMI when treating them with adjuvant chemotherapy.\u201d But she added: \u201cDosing chemotherapy is complex and includes not only weight but fitness, co-morbidities including renal function and dihydropyrimidine dehydrogenase (DPD) testing results.\u201d<\/p>\n

Smyth considered that more studies are needed before changing practice. \u201cProspective studies examining the impact of higher doses of chemotherapy may be needed, especially as there is an increase in the proportion of patients diagnosed with cancer and who are obese.\u201d For now, she concluded: \u201cWe should take all aspects of the patient into account when making chemotherapy dosing decisions. Dose reductions do seem to be associated with less good survival in this study, but these may still be required for safety.\u201d <\/strong><\/p>\n

Notes to Editors<\/h4>\n

Please make sure to use the official name of the meeting in your reports: ESMO World Congress on Gastrointestinal Cancer 2021<\/strong><\/p>\n

Official Congress Hashtag: #WorldGI2021<\/strong><\/p>\n

Disclaimer<\/h4>\n

This press release contains information provided by the author of the highlighted abstract and reflects the content of this abstract. It does not necessarily reflect the views or opinions of the ESMO WGI Organisers who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.<\/p>\n

References<\/h4>\n
    \n
  1. Abstract O-4 \u2018Average cumulative relative dose (ACRD) of adjuvant chemotherapy is more important than average relative dose intensity (ARDI) for colorectal cancer survival, with implications for treating obese patients: the OCTOPUS consortium\u2018 will be presented by Corinna Slawinski during Session VII: Presentation of Selected Colorectal Cancer Abstracts on Friday, 2 July, 08:00-12:00 CEST. Annals of Oncology<\/em>, Volume 32, Supplement 3, July 2021<\/li>\n
  2. Parkin et al. Excess adiposity and survival in patients with colorectal cancer: a systematic review (2014). 15(5): 434-451.<\/li>\n
  3. Griggs JJ, Bohlke K, Balaban EP et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO Guideline Update. J Clin Oncol 2021 DOI https:\/\/doi.org\/10.1200\/JCO.21.00471<\/li>\n<\/ol>\n
    \n

    O-4 – Average cumulative relative dose (ACRD) of adjuvant chemotherapy is more important than average relative dose intensity (ARDI) for colorectal cancer survival, with implications for treating obese patients: the OCTOPUS consortium<\/p>\n

    \n

    C. Slawinski<\/u>1<\/sup>, L. Malcomson1<\/sup>, J. Barriuso2<\/sup>, H. Guo1<\/sup>, A. Harkin3<\/sup>, T. Iveson4<\/sup>, R. Glynne-Jones5<\/sup>, C. Van de Velde6<\/sup>, A. Renehan2<\/sup>  
    1 University of Manchester, Manchester, United Kingdom, 2<\/sup> University of Manchester \/ The Christie NHS Foundation Trust, Manchester, United Kingdom, 3<\/sup> Cancer Research UK Glasgow Clinical Trials Unit, Glasgow, United Kingdom, 4<\/sup> University of Southampton, Southampton, United Kingdom, 5<\/sup> Mount Vernon Cancer Centre, Northwood, United Kingdom, 6<\/sup> Leiden University Medical Center, Leiden, Switzerland   
      
    Background<\/strong>: After curative surgery for colorectal cancer (CRC), some studies indicate poorer survival in obese patients. Adjuvant chemotherapy (ACT) for CRC is commonly capped at a body surface area (BSA) \u22652.2m2, potentially reducing chemotherapy average cumulative relative dose (ACRD) and average relative dose intensity (ARDI) in obese patients.    
      
    Methods<\/strong>: Individual participant-level data from MOSAIC, SCOT, PROCTORSCRIPT and CHRONICLE (CRC-ACT) randomised-trials, with derivable BMI, BSA and chemotherapy doses, were included from the OCTOPUS consortium. ARDI and ACRD were calculated as percentages of actual to expected (full BSA-based) dose intensity (cumulative dose\/treatment duration in weeks) or cumulative dose respectively, averaged across the drugs in the regimen. A two-stage random-effects meta-analyses of linear or Cox proportional hazards regression models were performed to explore BMI-ARDI\/-ACRD and ARDI-\/ACRD-survival relationships respectively. The primary outcome was disease-free survival (DFS), and secondary outcomes were overall (OS) and cancer-specific (CSS) survival, in addition to ARDI and ACRD. All models where adjusted for age, sex, performance status, t-stage and n-stage (in addition to BMI in the survival models).   
      
    Results<\/strong>: 7269 patients were eligible. BMI 5kg\/m2 increments were associated with a 2.04% reduction in cycle 1 dose (95% CI:-2.45,-1.64; p<0.001) and modest reductions in ACRD (-1.05% (-1.84, -0.26); p=0.009) and ARDI (-1.02% (-1.43, -0.62); p<0.001). Within study effect modification was demonstrated for ARDI (female vs. male: 1.55% (0.97, 2.13); p<0.001), but not ACRD (female vs. male: 0.88% (-0.14, 1.89); p=0.092).  
       
    ACRD 5% increments were associated with improved DFS (HR 0.953 (0.926, 0.980); p=0.001), OS (HR 0.931(0.908, 0.955); p<0.001) and CSS (HR 0.941(0.924, 0.959); p<0.001) survival. However, no significant relationship was demonstrated for ARDI (DFS HR 1.015 (0.967, 1.065); p =0.552; OS HR 1.035 (0.990, 1.081); p 0.134; CSS HR 1.022 (0.982, 1.064); p = 0.282), nor for sex-interactions for both ACRD and ARDI.   
      
    Conclusion<\/strong>: ACRD is more important than ARDI in determining survival. Elevated BMI is associated with a reduced cycle 1 dose and a modest ACRD reduction. These indirect effects through under-treatment might explain poorer survival in obese patients, rather than direct effects of obesity resulting from, for example, tumour biology.   
      
    Legal Entity Responsible for this Study:<\/strong> The authors.   
    Funding: <\/strong>This work was supported by Cancer Research UK via the funding to Cancer Research UK Manchester Centre: [C147\/A18083] and [C147\/A25254]. A.G. Renehan is supported by the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007).
    Disclosure:<\/strong> All authors have declared no conflicts of interest<\/p>\n<\/div>\n<\/div>\n

    Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    LUGANO, Switzerland – Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO World Congress on Gastrointestinal Cancer 2021 (1). Further findings showed that cumulative relative chemotherapy dose was associated with survival so may […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-27221","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/27221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=27221"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/27221\/revisions"}],"predecessor-version":[{"id":43726,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/27221\/revisions\/43726"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=27221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=27221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=27221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}